- Home
- FGEN vs VYNE Comparison
FGEN vs VYNE Comparison
Compare FGEN & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGEN
- VYNE
- Stock Information
- Founded
- FGEN 1993
- VYNE 2003
- Country
- FGEN United States
- VYNE United States
- Employees
- FGEN N/A
- VYNE N/A
- Industry
- FGEN Biotechnology: Pharmaceutical Preparations
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- FGEN Health Care
- VYNE Health Care
- Exchange
- FGEN Nasdaq
- VYNE Nasdaq
- Market Cap
- FGEN 33.5M
- VYNE 35.7M
- IPO Year
- FGEN 2014
- VYNE 2018
- Fundamental
- Price
- FGEN $0.31
- VYNE $1.30
- Analyst Decision
- FGEN Strong Buy
- VYNE Strong Buy
- Analyst Count
- FGEN 1
- VYNE 2
- Target Price
- FGEN $10.00
- VYNE $6.25
- AVG Volume (30 Days)
- FGEN 514.9K
- VYNE 220.5K
- Earning Date
- FGEN 05-12-2025
- VYNE 05-08-2025
- Dividend Yield
- FGEN N/A
- VYNE N/A
- EPS Growth
- FGEN N/A
- VYNE N/A
- EPS
- FGEN N/A
- VYNE N/A
- Revenue
- FGEN $29,621,000.00
- VYNE $605,000.00
- Revenue This Year
- FGEN $232.81
- VYNE N/A
- Revenue Next Year
- FGEN $9.16
- VYNE N/A
- P/E Ratio
- FGEN N/A
- VYNE N/A
- Revenue Growth
- FGEN N/A
- VYNE 43.03
- 52 Week Low
- FGEN $0.18
- VYNE $1.27
- 52 Week High
- FGEN $1.74
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- FGEN 46.75
- VYNE 34.90
- Support Level
- FGEN $0.28
- VYNE $1.27
- Resistance Level
- FGEN $0.34
- VYNE $1.41
- Average True Range (ATR)
- FGEN 0.02
- VYNE 0.12
- MACD
- FGEN 0.00
- VYNE -0.01
- Stochastic Oscillator
- FGEN 37.50
- VYNE 5.46
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.